Thromb Haemost 1993; 70(02): 263-265
DOI: 10.1055/s-0038-1649562
Original Articles
Clinical Studies
Schattauer GmbH Stuttgart

Congenital Histidine-Rich Glycoprotein Deficiency

Toshio Shigekiyo
1   The First Department of Internal Medicine, School of Medicine, the University of Tokushima, Tokushima, Japan
,
Tsutomu Ohshima
2   The Department of Neurosurgery, Anan Kyoei Hospital, Tokushima, Japan
,
Hirofumi Oka
2   The Department of Neurosurgery, Anan Kyoei Hospital, Tokushima, Japan
,
Akira Tomonari
1   The First Department of Internal Medicine, School of Medicine, the University of Tokushima, Tokushima, Japan
,
Hiroyuki Azuma
1   The First Department of Internal Medicine, School of Medicine, the University of Tokushima, Tokushima, Japan
,
Shiro Saito
1   The First Department of Internal Medicine, School of Medicine, the University of Tokushima, Tokushima, Japan
› Author Affiliations
Further Information

Publication History

Received 12 November 1992

Accepted after revision 16 February 1993

Publication Date:
04 July 2018 (online)

Summary

The proband, a 43-year-old woman, suffered from right transverse sinus thrombosis during oral contraceptive treatment. A month after stopping the drug, her plasma activities of antithrombin III, protein C, protein S, heparin cofactor II, plasminogen and plasminogen activator inhibitor were normal, but her plasma histidine-rich glycoprotein (HRG) level was only 21% of the normal level of 109.5 ± 51.5% (mean ± 2 SD). The HRG concentrations in her plasma determined on four different occasions over 6 months were similar. She showed no clinical signs of liver insufficiency or sepsis. Low levels of plasma HRG (20% to 35% of normal) were also found in her aunt, uncle and two daughters. These results suggest that congenital HRG deficiency is inheritary in this family.

 
  • References

  • 1 Heimburger N, Haupt H, Kranz T, Baudner S. Human serum proteins with a high affinity for carboxymethylcellulose, II: Physicochemical and immunological characterization of a histidine-rich 3.8 S α2 glycoprotein (CM protein I). Hoppe-Seyler’s Z Physiol Chem 1972; 353: 1133-1140
  • 2 Koide T, Foster D, Yoshitake S, Davie EW. Amino acid sequence of human histidine-rich glycoprotein derived from the nucleotide sequence of its cDNA. Biochemistry 1986; 25: 2220-2225
  • 3 Koide T. Human histidine-rich glycoprotein gene: Evidence for evolutionary relatedness to cystatin supergene family. Thromb Res 1988; (Suppl. 08) 91-97
  • 4 Morgan WT. Human serum histidine-rich glycoprotein. I. Interactions with heme, metal ions and organic ligands. Biochim Biophys Acta 1978; 535: 319-333
  • 5 Lijnen HR, Hoylaerts M, Collen D. Isolation and characterization of a human plasma protein with affinity for the lysine binding sites in plasminogen. Role in the regulation of fibrinolysis and identification as histidine-rich glycoprotein. J Biol Chem 1980; 255: 10214-10222
  • 6 Leung LLK, Nachman RL, Harpel PC. Complex formation of platelet thrombospondin with histidine-rich glycoprotein. J Clin Invest 1984; 73: 5-12
  • 7 Leung LLK. Interaction of histidine-rich glycoprotein with fibrinogen and fibrin. J Clin Invest 1986; 77: 1305-1311
  • 8 Lerch PG, Nydegger UE, Kuyas C, Haeberli A. Histidine-rich glycoprotein binding to activated human platelets. Br J Haematol 1988; 70: 219-224
  • 9 Saigo K, Shatsky M, Levitt LJ, Leung LLK. Interaction of histidine-rich glycoprotein with human T lymphocytes. J Biol Chem 1989; 264: 8249-8253
  • 10 Engesser L, Kluft C, Briét E, Brommer EJP. Familial elevation of plasma histidine-rich glycoprotein in a family with thrombophilia. Br J Haematol 1987; 67: 355-358
  • 11 Schleider MA, Nachman RL, Jaffe EA, Coleman M. A clinical study of the lupus anticoagulant. Blood 1976; 48: 499-509
  • 12 Exner T, Rickard KA, Kronenberg H. A sensitive test demonstrating lupus anticoagulant and its behavioural patterns. Br J Haematol 1978; 40: 143-151
  • 13 Laurell CB. Quantitative estimation of proteins by electrophoresis in agarose gel containing antibodies. Anal Biochem 1966; 15: 45-52
  • 14 Lijnen HR, Jacobs G, Collen D. Histidine-rich glycoprotein in a normal and a clinical population. Thromb Res 1981; 22: 519-523
  • 15 Silverstein RL, Nachman RL, Leung LLK, Harpel PC. Activation of immobilized plasminogen by tissue activator. Multimolecular complex formation. J Biol Chem 1985; 260: 10346-10352
  • 16 Vestergaard AB, Andersen HF, Magnusson S, Halkier T. Histidine-rich glycoprotein inhibits contact activation of blood coagulation. Thromb Res 1990; 60: 385-396
  • 17 Kazama Y, Koide T. Modulation of protein C inhibitor activity by histidine-rich glycoprotein and platelet factor 4: Role of zinc and calcium ions in the heparin-neutralizing ability of histidine-rich glycoprotein. Thromb Haemostas 1992; 67: 50-55
  • 18 Thaler E, Lechner K. Antithrombin III deficiency and thromboembolism. Clin Hematol 1981; 10: 369-390
  • 19 Bovill EG, Bauer KA, Dickerman JD, Callas P, West B. The clinical spectrum of heterozygous protein C deficiency in a large new England kindred. Blood 1989; 73: 712-717
  • 20 Engesser L, Broekmans AW, Briët E, Brommer EJP, Bertina RM. Hereditary protein S deficiency: clinical manifestations. Ann Intern Med 1987; 106: 677-682
  • 21 Girolami A, Simioni P, Girolami B, Zanardi S. The role of drugs, particularly oral contraceptives, in triggering thrombosis in congenital defects of coagulation inhibitors: a study of six patients. Blood Coag Fibrinol 1991; 2: 673-678
  • 22 Jespersen J, Kluft C. Decreased levels of histidine-rich glycoprotein (HRG) and increased levels of free plasminogen in women on oral contraceptives low in estrogen. Thromb Haemostas 1982; 48: 283-285